Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
09 Avril 2024 - 2:00PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced that management will participate in
one-on-one meetings at the Piper Sandler Spring Biopharma Symposium
2024 being held in Boston, Massachusetts on April 16-17, 2024.
Please contact your Piper Sandler representative to
schedule a one-on-one meeting.
About AligosAligos Therapeutics,
Inc. is a clinical stage biopharmaceutical company that was founded
in 2018 with the mission to become a world leader in the treatment
of liver and viral diseases. Aligos’ strategy is to harness the
deep expertise and decades of drug development experience its team
has in liver and viral diseases to discover and develop potentially
best-in-class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need
such as hepatitis B and coronaviruses.
CompanyJordyn TaraziVice
President, Investor Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaMichael Fitzhugh LifeSci
Communications (628) 234-3889mfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aligos Therapeutics (NASDAQ:ALGS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024